# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Vatroslav Mateljic's innovative approach and commitment to transforming the lives of patients will strengthen Takeda's ...
Truist Securities has initiated coverage on Protagonist Therapeutics, praising its first-in-class lead asset with promising Pha...
HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwr...
Increase in production of Takeda's ADHD drug Vyvanse, approved by DEA to address ongoing shortages both domestically and gl...
FDA grants approval to Ascendis Pharma's Yorvipath (TransCon PTH) for adult hypoparathyroidism. Yorvipath offers continuous...
Takeda Pharmaceutical stock rises following European Commission approval of Adzynma for treating ADAMTS13 deficiency in cTTP pa...
FY2024 Outlook (unchanged from May 2024) (Billion yen, except percentages and per share